Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer

The monoclonal antibodies cetuximab and panitumumab, directed against the epidermal growth factor receptor (EGFR), are licensed for the treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Such ‘molecular restriction’ derived from post-hoc analyses of randomized trials and from other ret...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Loupakis, Fotios, Cremolini, Chiara, Fontanini, Gabriella, Stasi, Irene, Salvatore, Lisa, Falcone, Alfredo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2009
Konular:
Reviews
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126002/
https://ncbi.nlm.nih.gov/pubmed/21789120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834009348984
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller